コンテンツへスキップ
Merck
すべての画像(1)

主要文書

すべての文書を表示

安全性情報

919489

Sigma-Aldrich

CCW16-C6-PEG3-butyl-BocNH

別名:

tert-butyl (6-(2-(2-((6-(4-(4-(N-Benzyl-2-chloroacetamido)phenoxy)phenoxy)hexyl)oxy)ethoxy)ethoxy)hexyl)carbamate, Crosslinker-E3 Ligase ligand conjugate, Protein degrader building block for PROTAC® research, RNF4-targeting building block, Template for synthesis of targeted protein degrader

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C42H59ClN2O8
分子量:
755.38
MDL番号:
MFCD34166226
NACRES:
NA.22

ligand

CCW16

品質水準

100

フォーム

viscous liquid

反応適合性

reactivity: carboxyl reactive
reagent type: ligand-linker conjugate

官能基

amine

保管温度

2-8°C

SMILES記法

O=C(CCl)N(CC1=CC=CC=C1)C2=CC=C(C=C2)OC3=CC=C(OCCCCCCOCCOCCOCCCCCCNC(OC(C)(C)C)=O)C=C3

InChI

1S/C42H59ClN2O8/c1-42(2,3)53-41(47)44-25-11-4-5-12-26-48-29-31-50-32-30-49-27-13-6-7-14-28-51-37-21-23-39(24-22-37)52-38-19-17-36(18-20-38)45(40(46)33-43)34-35-15-9-8-10-16-35/h8-10,15-24H,4-7,11-14,25-34H2,1-3H3,(H,44,47)

関連するカテゴリー

アプリケーション

Protein degrader building block CCW16-C6-PEG3-butyl-BocNH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a RING finger protein 4 (RNF4)-recruiting ligand, a linker with both hydrophobic and hydrophilic moieties, and a pendant amine for reactivity with a carboxylic acid on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a terminal amine, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

その他情報

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

法的情報

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

関連製品

製品番号
詳細
価格

904708

Pomalidomide-C6-PEG3-butyl iodide, ≥95%

904686

Pomalidomide-C6-PEG3-butyl azide, ≥95%

904821

(S,R,S)-AHPC-C6-PEG3-butyl azide, ≥95%

905232

(S,R,S)-AHPC-C6-PEG3-butyl amine hydrochloride, ≥95%

905208

Pomalidomide-C6-PEG3-butyl amine hydrochloride, ≥98%

905380

(S,R,S)-AHPC-C6-PEG3-butyl chloride, ≥95%

910546

(S,R,S)-AHPC-C6-PEG3-butyl alkyne, ≥95%

910511

Pomalidomide-C6-PEG3-butyl alkyne, ≥95.0%

919438

CCW16-C9-BocNH, ≥95%

919470

CCW16-PEG2-butyl-BocNH, ≥95%

919462

CCW16-PEG5-BocNH, ≥95%

919454

CCW16-PEG3-BocNH, ≥95%

919403

CCW16-C4-BocNH, 95%

919446

CCW16-PEG1-BocNH

919411

CCW16-C6-BocNH

919381

CCW16, ≥95%

保管分類コード

10 - Combustible liquids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

919489-BULK:
919489-50MG:
919489-VAR:

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

申し訳ございませんが、現在この製品のCOAをオンラインで入手できません。

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Carl C Ward et al.
ACS chemical biology, 14(11), 2430-2440 (2019-05-07)
Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 ligase recruiter to
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

資料

標的タンパク質分解のための分解物ビルディングブロック

タンパク質分解誘導化合物ビルディングブロックは、標的リガンドと共有結合するペンダント基を持つクロスリンカー-E3リガンド複合体です。

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）